Drug interactions
Efgartigimod / hyaluronidase sc + Rho human immunoglobulin
Severity: Moderate
Efgartigimod / hyaluronidase sc and Rho human immunoglobulin: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Subcutaneous efgartigimod blocks the neonatal Fc receptor and speeds IgG breakdown, which may lower exposure to Rho(D) immune globulin. This could reduce its protective effect against Rh alloimmunization.
What this interaction means in plain words
Efgartigimod / hyaluronidase sc and Rho human immunoglobulin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Efgartigimod blocks FcRn-mediated IgG recycling, increasing clearance of IgG-based Rho(D) immune globulin.
What to do
Monitor for adequate anti-D protection and consider timing Rho(D) immune globulin away from efgartigimod dosing. Reassess the need for efgartigimod in Rh-negative patients with Rh-incompatible exposure.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Efgartigimod / hyaluronidase sc and Rho human immunoglobulin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Frequently asked questions
Can I take Efgartigimod / hyaluronidase sc with Rho human immunoglobulin?
MediHelp rates the interaction as moderate. Efgartigimod / hyaluronidase sc and Rho human immunoglobulin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Subcutaneous efgartigimod blocks the neonatal Fc receptor and speeds IgG breakdown, which may lower exposure to Rho(D) immune globulin. This could reduce its protective effect against Rh alloimmunization.
How serious is the interaction between Efgartigimod / hyaluronidase sc and Rho human immunoglobulin?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for adequate anti-D protection and consider timing Rho(D) immune globulin away from efgartigimod dosing. Reassess the need for efgartigimod in Rh-negative patients with Rh-incompatible exposure.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
